More recently, Riluzole is shown to have anti-tumorigenic effects in prostate cancer cells via ER stress-induced degradation of androgen receptor, thereby decreasing expressions of target genes such as prostate specific antigen (PSA)60. The gene discussed is KLK3; the disease is prostate carcinoma.